BTG plc (LON:BTG)‘s stock had its “neutral” rating reaffirmed by JPMorgan Chase & Co. in a research report issued on Tuesday. They currently have a GBX 790 ($9.94) price target on the stock. JPMorgan Chase & Co.’s price target would suggest a potential upside of 22.96% from the company’s current price.

BTG has been the subject of several other reports. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 900 ($11.33) target price on shares of BTG plc in a report on Wednesday, January 25th. Panmure Gordon reaffirmed a “buy” rating and set a GBX 737 ($9.28) target price on shares of BTG plc in a report on Thursday, January 26th. Peel Hunt reaffirmed a “hold” rating and set a GBX 630 ($7.93) target price on shares of BTG plc in a report on Friday, February 24th. Jefferies Group LLC reaffirmed a “buy” rating and set a GBX 860 ($10.82) target price on shares of BTG plc in a report on Thursday, January 5th. Finally, Deutsche Bank AG lowered their target price on BTG plc from GBX 800 ($10.07) to GBX 775 ($9.75) and set a “buy” rating for the company in a report on Thursday, January 26th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of GBX 760.22 ($9.57).

Analyst Recommendations for BTG plc (LON:BTG)

Shares of BTG plc (LON:BTG) opened at 642.50 on Tuesday. BTG plc has a 12 month low of GBX 528.36 and a 12 month high of GBX 739.50. The stock’s market capitalization is GBX 2.47 billion. The company’s 50 day moving average price is GBX 595.26 and its 200 day moving average price is GBX 599.85.

TRADEMARK VIOLATION WARNING: “BTG plc’s (BTG) “Neutral” Rating Reaffirmed at JPMorgan Chase & Co.” was posted by Marea Informative and is the property of of Marea Informative. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at http://www.mareainformativa.com/btg-plc-btg-calificacion-de-acciones-reafirmado-por-parte-de-jpmorgan-chase-co/108653/.

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.